Dr Reddy's Laboratories Achieves Remarkable Growth in Q4

Dr Reddy's Laboratories announced a significant 21% year-on-year increase in consolidated net profit, reaching Rs 1,587 crore for the quarter ended March 2025. This impressive growth was fueled by strong sales in key markets such as the US and India.

Annual Financial Highlights

For the fiscal year 2024-25, the company reported a net profit of Rs 5,724 crore, marking a 3% growth over the previous year. Annual revenue saw a notable increase to Rs 32,553 crore from Rs 27,916 crore in FY24.

Strategic Growth and Future Plans

G V Prasad, Co-Chairman and Managing Director, highlighted the company's double-digit growth across businesses, attributing success to product launches and strategic acquisitions. Dr Reddy's remains committed to strengthening its operations through portfolio management and strategic partnerships.

Dividend Announcement and Leadership Continuity

The board has recommended a final dividend of Rs 8 per equity share for FY25 and approved the reappointment of G V Prasad as Co-Chairman and Managing Director for another five-year term.

Shares of Dr Reddy’s ended 0.67% higher at Rs 1,156.40 on the BSE, reflecting investor confidence in the company's growth trajectory.